Drugs / CD24Fc
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02650895 | Jun 2014 → Jan 2015 | — | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04060407 | Jun 2021 → Dec 2022 | metastatic melanoma | Merck & Co., Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04552704 | Oct 2020 → Feb 2021 | cancer | Tianhong Li | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03960541 | Aug 2020 → May 2021 | HIV infectious disease, hyperlipidemia | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02663622 | Sep 2016 → Jun 2020 | graft versus host disease, leukemia | Merck & Co., Inc. | Completed | Met primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT04095858 | Jan → Nov 2021 | acute graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04317040 | Apr → Oct 2020 | COVID-19 | Merck & Co., Inc. | Completed | Met primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-15 | Merck Sharp & Dohme LLC | MSD to Discontinue Development of MK-7110 for COVID-19 msd.com ↗ |
| 2021-04-15 | Merck Sharp & Dohme LLC | Merck to Discontinue Development of MK-7110 for COVID-19 merck.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD24Fc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04552704 ↗ |
| Known as | Cd24igg1fc | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297717 ↗ |
| Known as | Efprezimod alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02663622 ↗ |
| Known as | MK-7110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297717 ↗ |
| Known as | Saccovid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297717 ↗ |
| Action | Inhibit | “High mobility group protein B1 inhibitor” CHEMBL4297717 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain” NCT02650895 ↗ |
| Route | Intravenous | “Single dose of efprezimod alfa is administrated as intravenous infusion in one hour.” NCT02650895 ↗ |
| Target | HMGB1 | “High mobility group protein B1 inhibitor” CHEMBL4297717 ↗ |
| Target | SIGLEC10 | “Sialic acid-binding Ig-like lectin 10 modulator” CHEMBL4297717 ↗ |